Market Research Logo

Liquid Biopsy Market: Rising Cases of Lung Cancer Fuelling Adoption of Liquid Biopsy Across the World: Global Industry Analysis (2012 - 2016) and Opportunity Assessment (2017 - 2027)

Liquid Biopsy Market: Rising Cases of Lung Cancer Fuelling Adoption of Liquid Biopsy Across the World: Global Industry Analysis (2012 - 2016) and Opportunity Assessment (2017 - 2027)

This Future Market Insights (FMI) report examines the global liquid biopsy market for the period 2017–2027. The primary objective of the report is to offer insights into developments in the liquid biopsy market that are effecting global businesses and enterprises. This report covers the global liquid biopsy market performance in terms of revenue contribution from various segments. The report also includes in-depth analysis of key trends, drivers, restraints and opportunities, which are likely to influence growth of the global liquid biopsy market. Impact analysis of key growth drivers and restraints are included in this report to better equip clients with crystal clear decision-making insights. The liquid biopsy market report begins with an overview of the market and key definitions. This section also underlines factors influencing revenue growth of the liquid biopsy market along with a detailing of the key trends, drivers, restraints, and opportunities. Furthermore, FMI provides a competitive landscape of the top companies operating in the global liquid biopsy market along with their strategic developments.

The next few sections of the report analyse the global liquid biopsy market based on biomarker type, sample type, disease indication, and end user and present a comprehensive forecast in terms of value for the next 10 years. The next section of the report highlights the growth trends of the liquid biopsy market by region. It provides a market outlook for 2017–2027 and sets the forecast within the context of the global liquid biopsy market. The study discusses key regional trends contributing to the growth of the liquid biopsy market worldwide, as well as analyses the extent to which drivers are influencing this market in each region.

In the final section of the report on the global liquid biopsy market, a detailed competitive landscape is included to provide report audiences with a dashboard view of the leading market players along with information on the key differentiators among the competitor firms. Detailed company profiles presented in this section include company-specific long-term and short-term strategies, key offerings and recent developments in the global liquid biopsy market.

Research Methodology

While forecasting the revenue estimations for the global liquid biopsy market, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global liquid biopsy market. Another key feature of this report is the analysis of the different market segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity analysis is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective in the global liquid biopsy market.


1. Executive Summary
1.1. Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Liquid Biopsy Market View Point Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
3.3. Demand Side Drives
3.4. Supply Side Drivers
3.5. Restraints
3.6. Trends
3.7. Epidemiology Assessment
3.8. Reimbursement Scenario
3.9. Pipeline Assessment
3.10. Strategies and Price Impact
3.11. Case Study
4. North America Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027
4.1. Introduction
4.2. Regional Market Trends
4.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
4.3.1. U.S.
4.3.2. Canada
4.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
4.4.1. U.S.
4.4.2. Canada
4.5. Historical Market Size (US$ Mn) Trend Analysis By Biomarker Type, 2012–2016
4.5.1. CTC (Circulating Tumor Cells)
4.5.2. ctNA (Circulating Tumor Nucliec Acids)
4.5.3. Exosomes
4.6. Market Size (US$ Mn) Forecast By Biomarker Type, 2017–2027
4.6.1. CTC (Circulating Tumor Cells)
4.6.2. ctNA (Circulating Tumor Nucliec Acids)
4.6.3. Exosomes
4.7. Historical Market Size (US$ Mn) Trend Analysis By Sample Type, 2012–2016
4.7.1. Blood
4.7.2. Urine
4.7.3. Others
4.8. Market Size (US$ Mn) Forecast By Sample Type, 2017–2027
4.8.1. Blood
4.8.2. Urine
4.8.3. Others
4.9. Historical Market Size (US$ Mn) Trend Analysis By Disease Indication, 2012–2016
4.9.1. Lung Cancer
4.9.2. Gastrointestinal Cancer
4.9.3. Prostate Cancer
4.9.4. Breast Cancer
4.9.5. Colorectal Cancer
4.9.6. Leukemia
4.9.7. Others
4.10. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2027
4.10.1. Lung Cancer
4.10.2. Gastrointestinal Cancer
4.10.3. Prostate Cancer
4.10.4. Breast Cancer
4.10.5. Colorectal Cancer
4.10.6. Leukemia
4.10.7. Others
4.11. Historical Market Size (US$ Mn) Trend Analysis By End User, 2012–2016
4.11.1. Hospitals
4.11.2. Cancer Institutes
4.11.3. Academic Institutes
4.11.4. Diagnostic Centers
4.12. Market Size (US$ Mn) Forecast By End User, 2017–2027
4.12.1. Hospitals
4.12.2. Cancer Institutes
4.12.3. Academic Institutes
4.12.4. Diagnostic Centers
4.13. Drivers and Restraints: Impact Analysis
4.14. Market Attractiveness Analysis
4.14.1. By Country
4.14.2. By Biomarker Type
4.14.3. By Sample Type
4.14.4. By Disease Indication
4.14.5. By End User
5. Latin America Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027
5.1. Introduction
5.2. Regional Market Trends
5.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
5.3.1. Brazil
5.3.2. Mexico
5.3.3. Rest of Latin America
5.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
5.4.1. Brazil
5.4.2. Mexico
5.4.3. Rest of Latin America
5.5. Historical Market Size (US$ Mn) Trend Analysis By Biomarker Type, 2012–2016
5.5.1. CTC (Circulating Tumor Cells)
5.5.2. ctNA (Circulating Tumor Nucliec Acids)
5.5.3. Exosomes
5.6. Market Size (US$ Mn) Forecast By Biomarker Type, 2017–2027
5.6.1. CTC (Circulating Tumor Cells)
5.6.2. ctNA (Circulating Tumor Nucliec Acids)
5.6.3. Exosomes
5.7. Historical Market Size (US$ Mn) Trend Analysis By Sample Type, 2012–2016
5.7.1. Blood
5.7.2. Urine
5.7.3. Others
5.8. Market Size (US$ Mn) Forecast By Sample Type, 2017–2027
5.8.1. Blood
5.8.2. Urine
5.8.3. Others
5.9. Historical Market Size (US$ Mn) Trend Analysis By Disease Indication, 2012–2016
5.9.1. Lung Cancer
5.9.2. Gastrointestinal Cancer
5.9.3. Prostate Cancer
5.9.4. Breast Cancer
5.9.5. Colorectal Cancer
5.9.6. Leukemia
5.9.7. Others
5.10. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2027
5.10.1. Lung Cancer
5.10.2. Gastrointestinal Cancer
5.10.3. Prostate Cancer
5.10.4. Breast Cancer
5.10.5. Colorectal Cancer
5.10.6. Leukemia
5.10.7. Others
5.11. Historical Market Size (US$ Mn) Trend Analysis By End User, 2012–2016
5.11.1. Hospitals
5.11.2. Cancer Institutes
5.11.3. Academic Institutes
5.11.4. Diagnostic Centers
5.12. Market Size (US$ Mn) Forecast By End User, 2017–2027
5.12.1. Hospitals
5.12.2. Cancer Institutes
5.12.3. Academic Institutes
5.12.4. Diagnostic Centers
5.13. Drivers and Restraints: Impact Analysis
5.14. Market Attractiveness Analysis
5.14.1. By Country
5.14.2. By Biomarker Type
5.14.3. By Sample Type
5.14.4. By Disease Indication
5.14.5. By End User
6. Western Europe Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027
6.1. Introduction
6.2. Regional Market Trends
6.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
6.3.1. U.K.
6.3.2. Germany
6.3.3. France
6.3.4. Spain
6.3.5. Italy
6.3.6. NORDIC
6.3.7. BENELUX
6.3.8. Rest of Western Europe
6.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
6.4.1. U.K.
6.4.2. Germany
6.4.3. France
6.4.4. Spain
6.4.5. Italy
6.4.6. NORDIC
6.4.7. BENELUX
6.4.8. Rest of Western Europe
6.5. Historical Market Size (US$ Mn) Trend Analysis By Biomarker Type, 2012–2016
6.5.1. CTC (Circulating Tumor Cells)
6.5.2. ctNA (Circulating Tumor Nucliec Acids)
6.5.3. Exosomes
6.6. Market Size (US$ Mn) Forecast By Biomarker Type, 2017–2027
6.6.1. CTC (Circulating Tumor Cells)
6.6.2. ctNA (Circulating Tumor Nucliec Acids)
6.6.3. Exosomes
6.7. Historical Market Size (US$ Mn) Trend Analysis By Sample Type, 2012–2016
6.7.1. Blood
6.7.2. Urine
6.7.3. Others
6.8. Market Size (US$ Mn) Forecast By Sample Type, 2017–2027
6.8.1. Blood
6.8.2. Urine
6.8.3. Others
6.9. Historical Market Size (US$ Mn) Trend Analysis By Disease Indication, 2012–2016
6.9.1. Lung Cancer
6.9.2. Gastrointestinal Cancer
6.9.3. Prostate Cancer
6.9.4. Breast Cancer
6.9.5. Colorectal Cancer
6.9.6. Leukemia
6.9.7. Others
6.10. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2027
6.10.1. Lung Cancer
6.10.2. Gastrointestinal Cancer
6.10.3. Prostate Cancer
6.10.4. Breast Cancer
6.10.5. Colorectal Cancer
6.10.6. Leukemia
6.10.7. Others
6.11. Historical Market Size (US$ Mn) Trend Analysis By End User, 2012–2016
6.11.1. Hospitals
6.11.2. Cancer Institutes
6.11.3. Academic Institutes
6.11.4. Diagnostic Centers
6.12. Market Size (US$ Mn) Forecast By End User, 2017–2027
6.12.1. Hospitals
6.12.2. Cancer Institutes
6.12.3. Academic Institutes
6.12.4. Diagnostic Centers
6.13. Drivers and Restraints: Impact Analysis
6.14. Market Attractiveness Analysis
6.14.1. By Country
6.14.2. By Biomarker Type
6.14.3. By Sample Type
6.14.4. By Disease Indication
6.14.5. By End User
7. Eastern Europe Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027
7.1. Introduction
7.2. Regional Market Trends
7.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
7.3.1. Russia
7.3.2. Poland
7.3.3. Rest of Eastern Europe
7.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
7.4.1. Russia
7.4.2. Poland
7.4.3. Rest of Eastern Europe
7.5. Historical Market Size (US$ Mn) Trend Analysis By Biomarker Type, 2012–2016
7.5.1. CTC (Circulating Tumor Cells)
7.5.2. ctNA (Circulating Tumor Nucliec Acids)
7.5.3. Exosomes
7.6. Market Size (US$ Mn) Forecast By Biomarker Type, 2017–2027
7.6.1. CTC (Circulating Tumor Cells)
7.6.2. ctNA (Circulating Tumor Nucliec Acids)
7.6.3. Exosomes
7.7. Historical Market Size (US$ Mn) Trend Analysis By Sample Type, 2012–2016
7.7.1. Blood
7.7.2. Urine
7.7.3. Others
7.8. Market Size (US$ Mn) Forecast By Sample Type, 2017–2027
7.8.1. Blood
7.8.2. Urine
7.8.3. Others
7.9. Historical Market Size (US$ Mn) Trend Analysis By Disease Indication, 2012–2016
7.9.1. Lung Cancer
7.9.2. Gastrointestinal Cancer
7.9.3. Prostate Cancer
7.9.4. Breast Cancer
7.9.5. Colorectal Cancer
7.9.6. Leukemia
7.9.7. Others
7.10. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2027
7.10.1. Lung Cancer
7.10.2. Gastrointestinal Cancer
7.10.3. Prostate Cancer
7.10.4. Breast Cancer
7.10.5. Colorectal Cancer
7.10.6. Leukemia
7.10.7. Others
7.11. Historical Market Size (US$ Mn) Trend Analysis By End User, 2012–2016
7.11.1. Hospitals
7.11.2. Cancer Institutes
7.11.3. Academic Institutes
7.11.4. Diagnostic Centers
7.12. Market Size (US$ Mn) Forecast By End User, 2017–2027
7.12.1. Hospitals
7.12.2. Cancer Institutes
7.12.3. Academic Institutes
7.12.4. Diagnostic Centers
7.13. Drivers and Restraints: Impact Analysis
7.14. Market Attractiveness Analysis
7.14.1. By Country
7.14.2. By Biomarker Type
7.14.3. By Sample Type
7.14.4. By Disease Indication
7.14.5. By End User
8. Asia Pacific excluding Japan Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027
8.1. Introduction
8.2. Regional Market Trends
8.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
8.3.1. China
8.3.2. India
8.3.3. Australia and New Zealand
8.3.4. ASEAN
8.3.5. Rest of APEJ
8.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
8.4.1. China
8.4.2. India
8.4.3. Australia and New Zealand
8.4.4. ASEAN
8.4.5. Rest of APEJ
8.5. Historical Market Size (US$ Mn) Trend Analysis By Biomarker Type, 2012–2016
8.5.1. CTC (Circulating Tumor Cells)
8.5.2. ctNA (Circulating Tumor Nucliec Acids)
8.5.3. Exosomes
8.6. Market Size (US$ Mn) Forecast By Biomarker Type, 2017–2027
8.6.1. CTC (Circulating Tumor Cells)
8.6.2. ctNA (Circulating Tumor Nucliec Acids)
8.6.3. Exosomes
8.7. Historical Market Size (US$ Mn) Trend Analysis By Sample Type, 2012–2016
8.7.1. Blood
8.7.2. Urine
8.7.3. Others
8.8. Market Size (US$ Mn) Forecast By Sample Type, 2017–2027
8.8.1. Blood
8.8.2. Urine
8.8.3. Others
8.9. Historical Market Size (US$ Mn) Trend Analysis By Disease Indication, 2012–2016
8.9.1. Lung Cancer
8.9.2. Gastrointestinal Cancer
8.9.3. Prostate Cancer
8.9.4. Breast Cancer
8.9.5. Colorectal Cancer
8.9.6. Leukemia
8.9.7. Others
8.10. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2027
8.10.1. Lung Cancer
8.10.2. Gastrointestinal Cancer
8.10.3. Prostate Cancer
8.10.4. Breast Cancer
8.10.5. Colorectal Cancer
8.10.6. Leukemia
8.10.7. Others
8.11. Historical Market Size (US$ Mn) Trend Analysis By End User, 2012–2016
8.11.1. Hospitals
8.11.2. Cancer Institutes
8.11.3. Academic Institutes
8.11.4. Diagnostic Centers
8.12. Market Size (US$ Mn) Forecast By End User, 2017–2027
8.12.1. Hospitals
8.12.2. Cancer Institutes
8.12.3. Academic Institutes
8.12.4. Diagnostic Centers
8.13. Drivers and Restraints: Impact Analysis
8.14. Market Attractiveness Analysis
8.14.1. By Country
8.14.2. By Biomarker Type
8.14.3. By Sample Type
8.14.4. By Disease Indication
8.14.5. By End User
9. Japan Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027
9.1. Introduction
9.2. Regional Market Trends
9.3. Historical Market Size (US$ Mn) Trend Analysis By Biomarker Type, 2012–2016
9.3.1. CTC (Circulating Tumor Cells)
9.3.2. ctNA (Circulating Tumor Nucliec Acids)
9.3.3. Exosomes
9.4. Market Size (US$ Mn) Forecast By Biomarker Type, 2017–2027
9.4.1. CTC (Circulating Tumor Cells)
9.4.2. ctNA (Circulating Tumor Nucliec Acids)
9.4.3. Exosomes
9.5. Historical Market Size (US$ Mn) Trend Analysis By Sample Type, 2012–2016
9.5.1. Blood
9.5.2. Urine
9.5.3. Others
9.6. Market Size (US$ Mn) Forecast By Sample Type, 2017–2027
9.6.1. Blood
9.6.2. Urine
9.6.3. Others
9.7. Historical Market Size (US$ Mn) Trend Analysis By Disease Indication, 2012–2016
9.7.1. Lung Cancer
9.7.2. Gastrointestinal Cancer
9.7.3. Prostate Cancer
9.7.4. Breast Cancer
9.7.5. Colorectal Cancer
9.7.6. Leukemia
9.7.7. Others
9.8. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2027
9.8.1. Lung Cancer
9.8.2. Gastrointestinal Cancer
9.8.3. Prostate Cancer
9.8.4. Breast Cancer
9.8.5. Colorectal Cancer
9.8.6. Leukemia
9.8.7. Others
9.9. Historical Market Size (US$ Mn) Trend Analysis By End User, 2012–2016
9.9.1. Hospitals
9.9.2. Cancer Institutes
9.9.3. Academic Institutes
9.9.4. Diagnostic Centers
9.10. Market Size (US$ Mn) Forecast By End User, 2017–2027
9.10.1. Hospitals
9.10.2. Cancer Institutes
9.10.3. Academic Institutes
9.10.4. Diagnostic Centers
9.11. Drivers and Restraints: Impact Analysis
9.12. Market Attractiveness Analysis
9.12.1. By Biomarker Type
9.12.2. By Sample Type
9.12.3. By Disease Indication
9.12.4. By End User
10. Middle East & Africa Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
10.2.1. GCC Countries
10.2.2. South Africa
10.2.3. Rest of MEA
10.3. Market Size (US$ Mn) Forecast By Country, 2017–2027
10.3.1. GCC Countries
10.3.2. South Africa
10.3.3. Rest of MEA
10.4. Historical Market Size (US$ Mn) Trend Analysis By Biomarker Type, 2012–2016
10.4.1. CTC (Circulating Tumor Cells)
10.4.2. ctNA (Circulating Tumor Nucliec Acids)
10.4.3. Exosomes
10.5. Market Size (US$ Mn) Forecast By Biomarker Type, 2017–2027
10.5.1. CTC (Circulating Tumor Cells)
10.5.2. ctNA (Circulating Tumor Nucliec Acids)
10.5.3. Exosomes
10.6. Historical Market Size (US$ Mn) Trend Analysis By Sample Type, 2012–2016
10.6.1. Blood
10.6.2. Urine
10.6.3. Others
10.7. Market Size (US$ Mn) Forecast By Sample Type, 2017–2027
10.7.1. Blood
10.7.2. Urine
10.7.3. Others
10.8. Historical Market Size (US$ Mn) Trend Analysis By Disease Indication, 2012–2016
10.8.1. Lung Cancer
10.8.2. Gastrointestinal Cancer
10.8.3. Prostate Cancer
10.8.4. Breast Cancer
10.8.5. Colorectal Cancer
10.8.6. Leukemia
10.8.7. Others
10.9. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2027
10.9.1. Lung Cancer
10.9.2. Gastrointestinal Cancer
10.9.3. Prostate Cancer
10.9.4. Breast Cancer
10.9.5. Colorectal Cancer
10.9.6. Leukemia
10.9.7. Others
10.10. Historical Market Size (US$ Mn) Trend Analysis By End User, 2012–2016
10.10.1. Hospitals
10.10.2. Cancer Institutes
10.10.3. Academic Institutes
10.10.4. Diagnostic Centers
10.11. Market Size (US$ Mn) Forecast By End User, 2017–2027
10.11.1. Hospitals
10.11.2. Cancer Institutes
10.11.3. Academic Institutes
10.11.4. Diagnostic Centers
10.12. Drivers and Restraints: Impact Analysis
10.13. Market Attractiveness Analysis
10.13.1. By Country
10.13.2. By Biomarker Type
10.13.3. By Sample Type
10.13.4. By Disease Indication
10.13.5. By End User
11. Competition Landscape
11.1. Competition Dashboard
11.2. Company Profiles (Details – Overview, Financials, Strategy, SWOT, Recent Developments)
11.2.1. Biocept, Inc.
11.2.2. Qiagen N.V.
11.2.3. Trovagene, Inc.
11.2.4. Johnson & Johnson
11.2.5. MDxHealth SA
11.2.6. Natera, Inc.
11.2.7. F. Hoffman-La Roche Ltd.
11.2.8. Silicon Biosystems S.p.A.
11.2.9. Pathway Genomics Corporation
11.2.10. Sysmex Corporation
12. Global Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027, By Region
12.1. Introduction/Key Findings
12.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2012–2016
12.2.1. North America
12.2.2. Latin America
12.2.3. Western Europe
12.2.4. Eastern Europe
12.2.5. Asia Pacific excluding Japan
12.2.6. Japan
12.2.7. Middle East & Africa
12.3. Market Size (US$ Mn) Forecast By Region, 2017–2027
12.3.1. North America
12.3.2. Latin America
12.3.3. Western Europe
12.3.4. Eastern Europe
12.3.5. Asia Pacific excluding Japan
12.3.6. Japan
12.3.7. Middle East & Africa
12.4. Market Attractiveness Analysis By Region
13. Global Pain Therapeutic Solutions Market Analysis 2012–2016 and Forecast 2017–2027, By Biomarker Type
13.1. Introduction/Key Findings
13.2. Historical Market Size (US$ Mn) Trend Analysis By Biomarker Type, 2012–2016
13.2.1. CTC (Circulating Tumor Cells)
13.2.2. ctNA (Circulating Tumor Nucliec Acids)
13.2.3. Exosomes
13.3. Market Size (US$ Mn) Forecast By Biomarker Type, 2017–2027
13.3.1. CTC (Circulating Tumor Cells)
13.3.2. ctNA (Circulating Tumor Nucliec Acids)
13.3.3. Exosomes
13.4. Market Attractiveness Analysis By Biomarker Type
14. Global Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027, By Sample Type
14.1. Introduction/Key Findings
14.2. Historical Market Size (US$ Mn) Trend Analysis By Sample Type, 2012–2016
14.2.1. Blood
14.2.2. Urine
14.2.3. Others
14.3. Market Size (US$ Mn) Forecast By Sample Type , 2017–2027
14.3.1. Blood
14.3.2. Urine
14.3.3. Others
14.4. Market Attractiveness Analysis By Sample Type
15. Global Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication
15.1. Introduction/Key Findings
15.2. Historical Market Size (US$ Mn) Trend Analysis By Disease Indication, 2012–2016
15.2.1. Lung Cancer
15.2.2. Gastrointestinal Cancer
15.2.3. Prostate Cancer
15.2.4. Breast Cancer
15.2.5. Colorectal Cancer
15.2.6. Leukemia
15.2.7. Others
15.3. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2027
15.3.1. Lung Cancer
15.3.2. Gastrointestinal Cancer
15.3.3. Prostate Cancer
15.3.4. Breast Cancer
15.3.5. Colorectal Cancer
15.3.6. Leukemia
15.3.7. Others
15.4. Market Attractiveness Analysis By Disease Indication
16. Global Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027, By End User
16.1. Introduction/Key Findings
16.2. Historical Market Size (US$ Mn) Trend Analysis By End User, 2012–2016
16.2.1. Hospitals
16.2.2. Cancer Institutes
16.2.3. Academic Institutes
16.2.4. Diagnostic Centers
16.3. Market Size (US$ Mn) Forecast By End User, 2017–2027
16.3.1. Hospitals
16.3.2. Cancer Institutes
16.3.3. Academic Institutes
16.3.4. Diagnostic Centers
16.4. Market Attractiveness Analysis By End User
17. Global Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027
17.1. Market Size and Y-o-Y Growth
17.2. Absolute $ Opportunity
18. Assumptions and Acronyms Used
19. Research Methodology
List of Tables
Table 01: North America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 02: North America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Biomarker Type
Table 03: North America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Sample Type
Table 04: North America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication
Table 05: North America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User
Table 06: Latin America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 07: Latin America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Biomarker Type
Table 08: Latin America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Sample Type
Table 09: Latin America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication
Table 10: Latin America Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User
Table 11: Western Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 12: Western Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Biomarker Type
Table 13: Western Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Sample Type
Table 14: Western Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication
Table 15: Western Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User
Table 16: Eastern Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 17: Eastern Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Biomarker Type
Table 18: Eastern Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Sample Type
Table 19: Eastern Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication
Table 20: Eastern Europe Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User
Table 21: APEJ Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 22: APEJ Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Biomarker Type
Table 23: APEJ Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Sample Type
Table 24: APEJ Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication
Table 25: APEJ Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User
Table 26: Japan Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Biomarker Type
Table 27: Japan Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Sample Type
Table 28: Japan Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication
Table 29: Japan Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User
Table 30: MEA Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 31: MEA Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Biomarker Type
Table 32: MEA Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Sample Type
Table 33: MEA Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication
Table 34: MEA Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User
Table 35: Global Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Region
Table 36: Global Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Biomarker Type
Table 37: Global Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Sample Type
Table 38: Global Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication
Table 39: Global Liquid Biopsy Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report